A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
University Hospital Southampton NHS Foundation Trust
Merck Sharp & Dohme LLC
Australasian Leukaemia and Lymphoma Group
University College, London
Martin-Luther-Universität Halle-Wittenberg
University of Southampton
Konkuk University Medical Center
Martin-Luther-Universität Halle-Wittenberg
Newcastle-upon-Tyne Hospitals NHS Trust
Presage Biosciences
National Cancer Institute (NCI)
University College, London
University College, London
University Hospital Plymouth NHS Trust
Children's Oncology Group
Istituto Clinico Humanitas
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
Johann Wolfgang Goethe University Hospital
Trans Tasman Radiation Oncology Group
National Cancer Institute (NCI)